CollPlant Biotechnologies Ltd: A Plain-English Summary

I’ve put together this guide to help you understand how CollPlant Biotechnologies performed this year. My goal is to turn complex financial filings into clear information so you can decide if this company fits your investment strategy.

1. What does this company do?

CollPlant is an Israeli biotech firm that "grows" human tissue. They use a unique process to create human collagen (rhCollagen)—the protein that keeps skin and tissues healthy—using genetically engineered tobacco plants. This avoids the risks of animal-derived collagen, such as disease or immune rejection.

They focus on two main areas:

• Medical Aesthetics: They are developing regenerative fillers, like their flagship product vergenixSTR. These are designed to stimulate natural tissue growth rather than just filling space.
• 3D Bioprinting: They create "bio-inks" that act as scaffolding for 3D-printed organs. Their most notable partnership is with AbbVie to develop regenerative implants for breast reconstruction, a deal potentially worth over $100 million.

2. Financial performance: The "Cash Crunch"

The company is in a "growth" phase, meaning they spend much more than they earn.

• Revenue: In 2025, the company earned about $4.3 million, mostly from licensing fees and selling collagen for research.
• Losses: They reported an $11.5 million loss for 2025. While this is an improvement over their $16.6 million loss in 2024, they are still losing money, largely due to $8.2 million in research costs.
• The Big Picture: Since 2004, they have lost about $124.8 million. They have only been profitable once, in 2021, thanks to a one-time payment.
• Cash on Hand: As of December 31, 2025, they had $5.6 million in cash. Given their $9.8 million operational spend in 2025, they have less than 12 months of cash remaining.

3. The "Going Concern" Warning

This is the most critical part of the report: Auditors have raised "substantial doubt" about CollPlant’s ability to stay in business.

They are currently operating with limited capital. They must raise more cash within the next year to keep operating. If they choose to sell more shares to raise this money, your ownership percentage will shrink, which often lowers the stock price.

4. Key risks

Investing here is high-risk. Beyond their cash issues, keep these in mind:

• Reliance on Funding: They rely on government grants and partner payments. If a partner like AbbVie stops a program, the company loses both money and credibility.
• Manufacturing Scale: They have limited experience producing collagen at a massive scale. Moving from pilot production to large-scale manufacturing is a significant hurdle to fulfilling commercial orders.
• Regulatory Hurdles: Their products require expensive, years-long clinical trials to get FDA approval, with no guarantee of success.
• Geopolitical Risk: Being based in Israel, regional instability could disrupt their supply chain or limit their ability to attract international investment.

5. Future outlook

The company recently cut staff and narrowed their research focus to preserve capital. Their future depends on two things: raising more money and hitting clinical milestones with their partners. If they fail to secure additional funding or achieve these milestones, they may need to sell the company or cease operations.

---

Final Thought for Investors: CollPlant is a high-stakes play. You are essentially betting on their ability to secure more funding and successfully commercialize their bio-ink and aesthetic technologies before their current cash runs out. If you are considering an investment, weigh the potential of their proprietary technology against the very real risk of dilution or insolvency.